REperfusion With P2Y12 Inhibitors in Addition to mEchanical thRombectomy for perFUsion Imaging Selected Acute Stroke patiEnts (REPERFUSE)

REperfusion With P2Y12 Inhibitors in Addition to mEchanical thRombectomy for perFUsion Imaging Selected Acute Stroke patiEnts (REPERFUSE)

The main objective is to evaluate the efficacy of IV administration of the P2Y12 inhibitor (cangrelor) in addition to mecanich thrombectomy and WMD versus mecanich thrombectomy and WMD alone on the functional prognosis at 3 months, in patients with acute ischemic stroke eligible for mecanich thrombectomy on the basis of infusion imaging between 0 and 24 hours after the onset of symptoms.

Study Overview

• Status: Recruiting
• Conditions: Acute Ischemia
• Intervention / Treatment: Drug: Cangrelor; Other: best medical management

Detailed Description

The emergent reperfusion of the ischemic penumbra is the goal of acute ischemic stroke (AIS) treatment. Mechanical thrombectomy (MT) may be proposed up to 6 hours and from 6 to 24 hours after stroke onset if multimodal imaging demonstrates the presence of a substantial ischemic penumbra.

Despite the major benefit associated with MT, more than half of patients will remain disabled at 3 months. The rate of complete reperfusion after MT appears to be a major factor affecting functional outcome. However, this rate of complete reperfusion is only achieved in 50 % of the patients due to, at least in part, distal microcirculatory impairment and or erratic emboli.

In coronary artery disease, new antiplatelet agents, with a very short half-life, such as P2Y12 inhibitors (P2Y12I), have been shown to reduce in-stent thrombosis, myocardial infarction and death. The IV route for P2Y12 inhibitors administration is adapted to the stroke population who has frequently dysphagia that prevents per os drug administration. In addition, the very short half-life of the drug is quite interesting for the management of hemorrhagic complications or emergent surgical interventions and early antithrombotic secondary prevention initiation.

Hypothesis: subgroup of patients treated from 0 to 24 hours after onset with a demonstrated ischemic penumbra on perfusion imaging, the administration of P2Y12I in addition to MT and best medical management (BMM) may increase reperfusion rates and improve functional outcome compared to MT with BMM alone.

• Study Type: Interventional
• Enrollment (Estimated): 368
• Phase: Phase 3

Contacts and Locations

• Study Contact: Name: Amélie YAVCHITZ, MD, PhD; Phone Number: + 33 01 48 03 64 54; Email: ayavchitz@for.paris
• Study Contact Backup: Name: Mikael Pr MAZIGHI, Pr; Phone Number: + 33 01 48 03 65 65; Email: mmazighi@for.paris

Study Locations

• France
  • Besançon, France, 25030
    • Recruiting
    • CHU de Besançon
    • Contact: Guillaume, MD, PhD; Phone Number: + 33 03 81 66 89 37; Email: guillaume.charbonnier@univ-fcomte.fr
  • Bordeaux, France
    • Recruiting
    • Hôpital Pellegrin (CHU de Bordeaux)
    • Contact: Gaultier MARNAT, MD; Phone Number: + 33 05 56 79 56 79; Email: gaultier.marnat@chu-bordeaux.fr
  • Bron, France, 69500
    • Recruiting
    • Hospices civils de Lyon, Hôpital Pierre Wertheimer
    • Contact: Tae-Hee CHO, MD; Email: tae-hee.cho@chu-lyon.fr
  • Lille, France, 59037
    • Recruiting
    • Hôpital Salengro (CHU Lille)
    • Contact: Lucie DELLA SCHIAVA, MD; Phone Number: + 33 03 20 44 59 62; Email: Lucie.DELLASCHIAVA@CHRU-LILLE.FR
  • Limoges, France, 87000
    • Recruiting
    • Hôpital Dupuytren (CHU Limoges)
    • Contact: Aymeric ROUCHAUD, Pr; Phone Number: + 33 05 55 05 55 55; Email: AYMERIC.ROUCHAUD2@chu-limoges.fr
  • Marseille, France, 13005
    • Recruiting
    • CHU La Timone
    • Contact: Laurent SUISSA, MD-PhD; Phone Number: + 33 04 91 38 58 75; Email: laurent.suissa.@ap-hm.fr
  • Nancy, France, 54000
    • Recruiting
    • Hôpital Central (CHU de Nancy)
    • Contact: Benjamin GORY, Pr; Phone Number: + 33 03 83 85 95 27; Email: b.gory@chru-nancy.fr
  • Paris, France, 75019
    • Recruiting
    • Hôpital Fondation A de Rothschild
    • Contact: Mikael MAZIGHI, Pr; Phone Number: + 33 01 48 03 65 65; Email: mmazighi@for.paris
  • Paris, France, 75010
    • Recruiting
    • Hôpital Lariboisière AP-HP
    • Contact: Alexis, GUEDON; Phone Number: + 33 01 49 95 81 17; Email: alexis.guedon@aphp.fr
  • Paris, France, 75013
    • Recruiting
    • Hôpital Pitié-Salpêtrière AP-HP
    • Contact: Charlotte Rosso, Pr; Phone Number: + 33 01 42 16 18 54; Email: charlotte.rosso@aphp.fr
  • Strasbourg, France, 67200
    • Recruiting
    • CHU de Strasbourg
    • Contact: Raoul POP; Phone Number: + 33 03 88 12 27 87; Email: raoul.pop@chu-strasbourg.fr
  • Suresnes, France, 92150
    • Recruiting
    • Hopital Foch
    • Contact: Bertrand LAPERGUE, MD; Phone Number: + 33 01 46 25 59 73; Email: b.lapergue@hopital-foch.com
  • Toulouse, France, 31300
    • Recruiting
    • Hôpital Purpan (CHU de Toulouse)
    • Contact: Lionel CALVIERE, MD; Phone Number: + 33 05 61 77 94 86; Email: calviere.l@chu-toulouse.fr

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 80 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Age 18 or older
• Anterior circulation intracanial large artery occlusion isolated (Intracranial ICA and/or MCA) proved on CTA or MRA.
• Symptoms onset < 24h at imaging

• Indication for MT and fulfillment of the following brain imaging criteria :

  1. Perfusion imaging: An initial infarct volume (ischemic core on DWI or CTP calculated by the RAPID software) of less than 70 ml, a ratio between the critically hypoperfused lesion volume (calculated by RAPID with a TMax>6s) and initial infarct volume of 1.8 or more, and an absolute difference between those 2 volumes of 15 ml or more.

     OR (if perfusion imaging not available or uninterpretable) :

  2. CORE CLINICAL MISMATCH: Core calculated on DWI by RAPID, <25 mL if NIHSS 6-20 and <50 mL if NIHSS>20

     OR (if RAPID results are not considered reliable by the clinician) :

  3. CORE CLINICAL MISMATCH according to the clinician evaluation
• Pre-stroke mRS ≤ 2
• NIHSS ≥ 6

Exclusion Criteria:

• Contraindication to MT
• Patient over 80 years old with >10 microbleeds on pre-treatment MRI
• Pre-existing dependency with mRS ≥3.
• Known tandem ICA-MCA occlusions requiring stenting
• ASPECT<6 on NCCT or DWI-MRI
• Known hypersensitivity to cangrelor or to any of the excipients (mannitol, sorbitol)
• History of previous intracranial hemorrhage
• Evidence of active bleeding or acute trauma (fracture) on examination
• Recent surgery with a significant risk of bleeding
• VKA oral anticoagulation with INR >1.7
• Curative heparin or direct oral anticoagulants (DOACs) in previous 48 hours with specific DOAC dosage ≥50 ng/ml and abnormal thrombin time for patients on dabigatran or abnormal specific anti-Xa activity for patients on apixaban, edoxaban, or rivaroxaban
• Platelet count <100 000/ mm3
• Woman of childbearing age without a pregnancy test or with a positive serum pregnancy test
• Patient benefiting from a legal protection
• Non-membership of a national insurance scheme
• Opposition of the patient or (in case of inclusion as a matter of urgency) of the trustworthy person
• Participation in another study regarding AIS care interfering with this study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Cangrelor group; treated by P2Y12 inhibitor (cangrelor) in addition to MT and BMM. The dose of cangrelor will be started with a 30 micrograms/kg IV bolus over 1 minute right after randomization and before MT. The bolus will be immediately followed with 4 micrograms/kg/min IV infusion for the duration of MT up to 4 hours. Cangrelor infusion will be stopped at the end of the MT procedure and will not go further 4 hours. Transition to oral antiplatelet therapy will be possible 1 hour after cangrelor infusion discontinuation. No other anti-thrombotic drug is authorized during cangrelor infusion. MT technique choice is left to the investigator decision.	Drug: Cangrelor; administration of cangrolor by iv befor thrombectomy
Active Comparator: Best medical management group; treated by BMM associated to MT. Anti-thrombotic including alteplase are authorized if they follow the recommendations of the international guidelines. If alteplase infusion is given, no other anti-thrombotic drug is allowed for the following 24 hours. MT technique choice is left to the choice of the investigator.	Other: best medical management; used yhe best medical management

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Favorable functional evaluation at 3 month for patients with acute ischemic strocke treated by cangrelor.	The favorable functional outcome at 3 month will be evaluated using a modified Rankin Scale (mRS). The scale runs from 0 to 6, running from perfect health without symptoms to death (0: no symptoms, 3: Moderate disability. Requires some help, but able to walk unassisted, 6: Dead).	3 months

Collaborators and Investigators

• Sponsor: Fondation Ophtalmologique Adolphe de Rothschild
• Collaborators: Ministry of Health, France

Study record dates

Study Major Dates

• Study Start (Actual): March 2, 2022
• Primary Completion (Estimated): March 1, 2030
• Study Completion (Estimated): September 1, 2030

Study Registration Dates

• First Submitted: November 24, 2020
• First Submitted That Met QC Criteria: December 9, 2020
• First Posted (Actual): December 14, 2020

Study Record Updates

• Last Update Posted (Actual): March 2, 2026
• Last Update Submitted That Met QC Criteria: February 27, 2026
• Last Verified: February 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Vascular Diseases; Cardiovascular Diseases; Pathologic Processes; Stroke; Ischemia; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Neurotransmitter Agents; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Purinergic P2 Receptor Antagonists; Purinergic Antagonists; Purinergic Agents; cangrelor
• Other Study ID Numbers: MMI_2020_35

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No